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Sepsis is associated with significant morbidity and mortality if not promptly recognized and treated. Since the
development of early goal-directed therapy, mortality rates have decreased, but sepsis remains a major cause of death
in patients arriving at the emergency department or staying in hospital. In this forum article, we asked clinicians and
researchers with expertise in sepsis care to discuss the importance of rapid detection and treatment of the
condition, as well as special considerations in different patient groups.
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Donald M. Yealy (Figure 1) and David T. Huang (Figure 2)
Described for centuries, sepsis is a maladaptive inflam-
matory response to infection, creating profound symp-
toms and poor outcomes, including high short-term
mortality [1,2]. Even into the late 1990s, our experiences,
expectations, and insight into the care of the septic pa-
tient were dismal and grim. We knew that inflammatory
mediators, coagulation, cellular oxygen processing, and
both macro- and micro-circulation could be disturbed;
the cascading interaction(s) created the dismal outcomes
that we dutifully reported and lamented. Half or more of
those afflicted died during hospitalization, and we inter-
vened after organ failure was clear using promising
biologics that seemed to fix some facets but did not
improve mortality or function after recovery.
In 2001, Rivers et al. [3] explored a newer approach,
termed Early Goal-Directed Therapy (EGDT). The
conceptual model of EGDT was that sepsis and, in some
instances, septic shock are under-recognized and hence
under-treated. Rather than target mediators and individ-
ual organ or cellular events, Rivers et al. [3] sought to
limit the global oxygen deficits accompanying sepsis to
thwart the cycle of ‘evil humors running amok’ and
creating dysfunction. EGDT attempted to achieve this byFull list of author information is available at the end of the article
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unless otherwise stated.guiding the first 6 hours of resuscitation with central
venous pressure and saturation measures. The struc-
tured EGDT approach delivered more fluids (5 L mean)
in the first 6 hours, more inotropic support, and more
frequent red blood cell transfusion than an unstructured
approach. This EGDT use translated into a 16% absolute
mortality benefit compared to controls, the most stark
noted in sepsis care. Based on this, many called for central
catheter-driven EGDTcare for all with septic shock [4].
Follow-up work replicated the general observation that
earlier recognition, coupled with resuscitative care, im-
proved outcomes [5]. Often, the sites involved had little
pre-existing focus on sepsis recognition and care; even
when the full EGDT protocol was not implemented – a
common event – outcomes improved, suggesting that
one path to improved care was possible.
At the same time, others noted a parallel opportunity
with another sepsis care target – source control with an-
tibiotics. Delays in delivering appropriate antibiotics led
to higher mortality, akin to delayed resuscitation [6].
Coupling these therapeutic insights with the observation
that much of the hospitalized sepsis population receives
initial care in the emergency department reinforced the
importance of early care [7].
Recent research helped clarify the key messages of
what early care should be. Jones et al. [8] demonstrated
that early resuscitation in the first 6 hours after an
aggressive search for sepsis/septic shock using bedsidehis is an Open Access article distributed under the terms of the Creative
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suscitation assessment) was non-inferior to the more
regimented and resource-intensive EGDT approach sug-
gested by Rivers et al. [3], delivering hospital mortality
rates of 17 to 23%. Our ProCESS trial examined 1,351
patients in 30 US sites, assessing three approaches to re-
suscitation after early recognition and antibiotic therapy:
EGDT with the mandated central oximetric catheter
guiding care; a simpler but team-based and clinically-
driven protocol; or bedside care tailored by the treating
physician (usual care) [9]. The groups received a mean
of 4.3 to 5.3 L of fluids through hour 6 of resuscitation
and varying amounts of pressor, blood, and inotrope use.
Despite the aggressive but varying approaches between
those treated in each arm, we observed that how fluids
and vasoactive agents were provided did not create a su-
perior outcome as long as each was done early, aggres-
sively, and in the backdrop of early antibiotic use. The
60-d hospital mortality amongst the three arms ranged
from 18 to 21%, and the secondary outcomes, including
organ support and longer term recovery, also did notdiffer. The ARISE trial, based in Australia/New Zealand,
also studied EGDT compared to usual, unstructured care
in 1,600 patients with early recognition and infection
source control [10]. Like ProCESS, the two different
methods of resuscitation in ARISE did not identify one
as better and the overall outcomes were improved com-
pared to a decade prior. A separate national surveillance
study from Australia/New Zealand confirmed that these
lower hospital mortality rates are not simply research or
coding aberrations and are due, in part, to earlier care
efforts [11].
Where are we at?
Despite advances, sepsis remains one of the most deadly
emergency department arrival or hospital-acquired con-
ditions. Initial sepsis care remains uneven and often
sluggish [12]. Long term outcomes show an accrual of
death at 1 year after a bout of septic shock exceeding
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vors [14]. While awaiting newer tools to aid detection or
treat those who do not respond, we need to focus on
wider use of “egdt” – early and simple detection coupled
with the goals of fluids that are adequate and directed by
bedside reassessment and appropriate antibiotic therapy
– rather than any one singular prescriptive form of re-
suscitation. Early care matters – not so much a man-
dated catheter or prescriptive approach – and returning
to the days of delayed action is not an option.
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How can we improve the recognition of sepsis?
Anthony Delaney (Figure 3)
Sepsis remains a leading cause of mortality worldwide.
While there has been a measureable reduction in mor-
tality over recent years [11], the underlying reasons for
this decline in mortality are not entirely clear. More than
100 trials of specific treatments designed to improve
mortality in sepsis have failed to demonstrate a mortality
benefit [15]. It is possible that further research will lead
to a discovery of a novel agent capable of altering theFigure 3 Anthony Delaney, MBBS, MSc, PhD, FACEM, FCICM, is
a Fellow of the Australasian College for Emergency Medicine
and the College of Intensive Care Medicine. He is a Senior Staff
Specialist in the Malcolm Fisher Department of Intensive Care
Medicine at Royal North Shore Hospital, a Senior Lecturer at Sydney
Medical School, University of Sydney, and an adjunct Senior
Research Fellow at the Australian and New Zealand Intensive Care
Research Centre, in the Department of Epidemiology and
Preventative Health at Monash University.complex interaction between the specific pathogenic
mechanisms of various infective agents, the generic host
inflammatory reaction to infection, and the pathophysio-
logical response mediated by each individuals’ co-
morbidities, in a positive fashion, although such a ther-
apy would appear remote from clinical practice at this
point in time. As described in the previous section, the
EGDT resuscitation strategy [3] changed the landscape
in the management of the early stages of patients with
severe sepsis and septic shock. Although subsequent tri-
als [9,10] have not confirmed the benefits of this specific
resuscitation algorithm, it is considered that early recogni-
tion of sepsis and early application of the fundamental
principles of the treatment of sepsis, namely resuscitation,
antibiotics, and source control, may have contributed to
the gradual decline in mortality over recent times. One of
the major challenges facing clinicians is to identify and
recognize patients with sepsis and impending organ dys-
function, in the pre-hospital setting, in the emergency de-
partment, and for patients who deteriorate in hospital.
Attention to the pre-hospital phase in patients with
sepsis is clearly critical. The initial link in this chain is to
increase awareness of the symptoms of sepsis amongst
the general public. Organizations such as the Global
Sepsis Alliance and initiatives like World Sepsis Day,
which work to raise awareness of sepsis, play a crucial
role in alerting the general public about the importance
of seeking medical attention when they or a loved one
displays the symptoms of sepsis. Pre-hospital care also
plays an important role in recognizing and providing
prompt care for patients with sepsis. Approximately 50%
of the patients who present to the emergency department
with sepsis will arrive via an Emergency Medical Service
(EMS) [16]. This exposure provides an excellent oppor-
tunity to improve early recognition of sepsis and to com-
mence an integrated system of care for these complex
patients. For example, in a pilot prospective cohort study
conducted in the pre-hospital setting, early identification
of patients with severe sepsis by EMS providers utilizing a
screening tool and a point-of-care venous lactate meter
was shown to be feasible [17]. Once identified, there is
scope for interventions, such as intravenous cannulation
and initiation of intravenous fluids provided pre-hospital,
to influence the outcomes of patients with sepsis [18].
An enhanced focus on the identification of sepsis in
the emergency department setting, as recommended by
the Surviving Sepsis Campaign Guidelines [4], has been
shown in numerous studies to be associated with im-
proved outcomes [19]. Identifying patients with sepsis in
a busy emergency department may be aided by the use
of electronic sepsis alert systems [20], or a screening tool
that combines simple clinical characteristics with the use
of early lactate measurements [21]. Simple tools have
been combined in successful large-scale quality
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paign, run by the Clinical Excellence Commission in
NSW, Australia [22], and the Surviving Sepsis Campaign
[23]. It is very likely that the increased focus on sepsis
by clinical champions, and the awareness amongst front
line staff regarding the possibility of sepsis that accom-
panies such campaigns, is responsible for much of the
improved outcomes demonstrated in these programs.
Identifying patients who deteriorate within the hospital
secondary to sepsis presents an additional challenge.
These populations often have concurrent medical or sur-
gical conditions that confound the diagnosis, making
early recognition difficult. The widespread introduction
of rapid response systems has led to the early identifica-
tion and the initiation of early intervention to patients
within the hospital system [24], many of whom will de-
teriorate secondary to sepsis. One other area that offers
ongoing promise with regards to the early identification
of patients with sepsis is the use of biomarkers. These
may be applicable to patients in the emergency depart-
ment and within the hospital. Traditional individual
markers of sepsis, such as the total white cell count,
neutrophil count, and C-reactive protein, lack the speci-
ficity to allow them to discriminate between those pa-
tients with an inflammatory response to trauma or
surgery, for example, and those with a new infection.
The best studied of the newer biomarkers of sepsis, pro-
calcitonin, which has been investigated in more than
3,000 patients suspected of sepsis [25], does not have
sufficient sensitivity to identify all cases of sepsis reliably,
nor the specificity to rule out sepsis when negative.
Other tests, such as the soluble triggering receptor
expressed on myeloid cells-1 (sTREM-1), offer some
promise, but still have inadequate sensitivity and specifi-
city to be used as a single biomarker for sepsis. Panels of
biomarkers, including sTREM-1, procalcitonin, CD 64
expression on neutrophils, and C-reactive protein, as
well as other novel biomarkers, offers some promise as
diagnostic markers of sepsis yet to be confirmed in large
scale clinical trials [26]. Table 1 summarizes the sensitiv-
ity and specificity of selected biomarkers for sepsis.Table 1 Sensitivity and specificity of selected biomarkers
for the diagnosis of sepsis
Sensitivity Specificity
(95% confidence
interval)
(95% confidence
interval)
C-reactive protein [58] 0.75 0.67
(0.62–0.84) (0.56–0.77)
Procalcitonin [25] 0.77 0.79
(0.72–0.81) (0.74–0.84)
STREM-1 [59] 0.79 0.8
(0.65–0.89) (0.69–0.88)There are still challenges to be overcome with regards
to improving the early recognition of sepsis. The current
definition of sepsis [4] remains overly complex and diffi-
cult to use in a clinical setting. A new definition, incorp-
orating simple clinical measures, may greatly enhance
the evolving clinical science as well as the clinical prac-
tice of diagnosing early sepsis. Identifying the best sepsis
screening tools, and refining a biomarker or set of bio-
markers to definitively identify patients who have sepsis,
is a major challenge. These challenges need to be ad-
dressed so that, in populations with altered physiology,
such as women who are pregnant or in the early post-
partum, period, or those in whom clinical features may
be non-specific, such as infants and children, the diagno-
sis of sepsis can be made and the important early inter-
ventions can be commenced in an expedient fashion.Competing interests
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Marian Knight (Figure 4)
Sepsis is an important cause of both morbidity and mor-
tality in pregnancy and the postpartum period; approxi-
mately one in every thousand women giving birth will
develop sepsis, with half of these women progressing to se-
vere sepsis and 3 to 4% developing septic shock [27]. Ma-
ternal sepsis is a challenge in both low- and high-resource
settings; one-quarter of women who die within the 6 weeks
after pregnancy in the UK die from sepsis [28]. Globally, an
estimated 11% of maternal deaths are caused by sepsis, the
vast majority occurring in developing regions [29].
There are several well-recognized risk factors for ma-
ternal sepsis, including the presence of pre-existing med-
ical conditions such as anemia, febrile illness in the
2 weeks prior to diagnosis of sepsis, and, most notably,
mode of delivery [30]. Cesarean delivery and operative
vaginal delivery are both associated with severe maternal
sepsis [31]. The predominant causes of maternal sepsis
vary according to the timing of infection; antenatally, in-
fections of the urinary tract make up about one-third of
all cases of maternal sepsis, whereas postnatally, one-
third of sepsis is due to genital tract infections [31].
Overall, infections due to E. coli are most numerous, but
infections with Group A Streptococcus are significantly
associated with greater severity of sepsis [31]. There is
good evidence that pregnant women are at higher risk of
complications of certain specific infections, for example,
influenza, varicella zoster, and listeria.
Figure 4 Marian Knight is Professor of Maternal and Child
Population Health, NIHR Research Professor and Honorary
Consultant in Public Health at the National Perinatal
Epidemiology Unit, University of Oxford. Her research interests
include severe maternal morbidity and the use of population-based
observational studies to address key clinical questions in obstetrics.
Since 2012, she has led the UK Confidential Enquiries into Maternal
Deaths and Morbidity, which most recently focused on maternal sepsis.
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and fit and compensate well, even in the presence of severe
infection [32]. Infection may thus be well established before
a diagnosis of sepsis is made. Early consideration of the diag-
nosis and, hence, early recognition is therefore perhaps even
more critical in the obstetric population. This is dependent
on both the measurement of vital signs in any unwell preg-
nant or postpartum woman, as well as acting on the findings
[28]. Although pregnancy and childbirth is a normal physio-
logical process, normality cannot be assumed in the presence
of abnormal signs or symptoms. It is important to note that
symptoms, such as severe abdominal pain, breathlessness,
and diarrhea, may be associated with postpartum sepsis.
Additionally, maternal sepsis should always be considered as
part of the differential diagnosis in a postpartum woman pre-
senting with shock. Although hemorrhage is the commonest
cause of shock in a postpartum woman, possible sepsis must
be investigated, particularly if blood loss is only moderate
and treatment for hemorrhage appears ineffective.In relation to maternal shock, it is important to be
aware of the significance of Group A Streptococcal in-
fection. Although cesarean delivery and operative vaginal
delivery are both risk factors for maternal sepsis, Group
A Streptococcal infections are proportionately more fre-
quently seen in women who have had an unassisted vaginal
delivery. Group A Streptococcal infection is a known risk
factor for development of septic shock, and is associated
with rapid sepsis progression [31]. In a UK national study
of severe maternal sepsis, for 75% of women with a Group
A Streptococcal infection there was less than 9 hours be-
tween the first signs of systemic inflammatory response
syndrome and the diagnosis of severe sepsis [31]. In 50% of
women this was less than 2 hours.
As with sepsis in general populations, along with early
recognition and diagnosis, the key action for manage-
ment is to institute a sepsis care bundle, including
administration of timely antibiotics (within 1 hour of
suspected sepsis), adequate fluid resuscitation, and the
measurement of serum lactate [28]. There is no specific
sepsis care bundle suggested for use in pregnancy or the
postpartum period; several have been recommended,
including the Surviving Sepsis Campaign resuscitation
care bundles [4], the Institute for Healthcare Improve-
ment severe sepsis bundles [33], and the ‘Sepsis Six Care
Bundle’ from the UK Sepsis Trust [34]. The choice of
antibiotic is dependent on the likely source of infection,
taking into account known hospital and individual fac-
tors such as prevalence of antibiotic resistant organisms
and mode of delivery. Adjustment may be made later
based on the woman’s response and subsequent culture
results.
Source control is essential in the timely management
of maternal sepsis; bearing in mind that this may require
cesarean delivery, hysterotomy, or hysterectomy in
women with genital tract sepsis. The UK and Ireland
Confidential Enquiry into Maternal Deaths identified a
number of women who subsequently died from maternal
sepsis following delayed delivery [28]. In several women,
delivery was delayed because the fetus had already died
and there was a perceived need to ensure the woman de-
livered vaginally. Failure to deliver the fetus and placenta
early in this situation will lead to a persisting source of
infection and progression of the woman’s sepsis despite
adequate resuscitation and antibiotic treatment.
Some evidence suggests that rates of maternal sepsis
may be increasing [27], and with more than an estimated
30,000 maternal deaths from sepsis annually [29], on-
going awareness of the diagnosis, timely recognition,
and management is vital.Competing interests
The author declares that she has no competing interests.
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Adrienne G. Randolph (Figure 5)
Overwhelming infection is the major cause of death in
children worldwide [35]. Neonates and young infants are at
highest risk because their immature immune systems are
less able to ward off severe pathogens [35,36]. Sepsis – when
a patient has a systemic inflammatory response to a sus-
pected or confirmed infection [37] – is a useful construct
in that it should bring the clinician to the bedside to exam-
ine the child and determine the proper treatment course.
Children who develop signs of severe sepsis with organ
dysfunction, and especially those who develop septic shock,
are at highest risk of life-threatening and fatal complica-
tions. In recent years, the approach to treating septic shock
in the pediatric patient has focused on early recognition of
severe sepsis. This is followed by rapid treatment with anti-
biotics and aggressive treatment of shock with fluid bolusesFigure 5 Adrienne Randolph is a Senior Associate in Critical
Care at Boston Children’s Hospital and a Professor of
Anesthesia at Harvard Medical School. She founded the Pediatric
Acute Lung Injury and Sepsis Investigator’s (PALISI) Network, a
voluntary network of over 80 large pediatric centers across the US
and Canada. This network has performed numerous observational
studies and clinical trials in children with severe infections. She
currently directs Pediatric Intensive Care Influenza and Emerging
Severe Pathogens (PICLFU-ESP), a network of investigators with
studies funded by the NIH and CDC.and, if refractory, with vasoactive agents. These interven-
tions, extrapolated from the care of septic adults, have
been widely disseminated as clinical guidelines [4]. Imple-
mentation of these interventions as care bundles with audit
and feedback can optimize clinician compliance [38]. Al-
though no large multi-center randomized trials have been
performed, there is some evidence that implementation of
early sepsis recognition, prompt delivery of antibiotics, and
intravenous fluids have improved clinical outcomes [4].
There is very strong evidence that focused attention on
constantly adhering to the use of central-line insertion and
maintenance bundles can prevent nosocomial sepsis from
central line-associated bloodstream infections [39].
Early sepsis recognition and aggressive treatment are ne-
cessary but insufficient. Treatment of ‘sepsis’ should rapidly
evolve into a specific diagnosis with targeted antimicrobial
therapy against the bacterial, viral, fungal or protozoal in-
vading pathogen. The most common infection in children
is pneumonia, the majority caused by viral pathogens [40].
Therefore, despite their widespread use, antibiotics are in-
effective for most children with a severe infection. With
the exception of influenza, antivirals are also usually not in-
dicated in immune competent hosts. The rapid implemen-
tation of strategies aimed at decreasing use of antibiotics is
also not without risk. Children with life-threatening viral
infections are frequently co-infected with highly patho-
genic bacteria. In recent years, methicillin-resistant
Staphylococcal aureus or MRSA, which used to be rela-
tively rare in children, has taken a rising toll; influenza-
MRSA is an especially fatal combination [41].
Although pediatric sepsis is common, no large-scale epi-
demiologic study has been performed to refine the widely
used pediatric sepsis diagnostic criteria [37]. These criteria
were originally developed for identifying children eligible
to participate in a drug trial and not for clinical manage-
ment. Tachypnea, tachycardia, fever, and alterations in
leucocyte count are sensitive indicators, but they encom-
pass many non-infectious acute inflammatory disorders.
Delayed capillary refill, lethargy, and other signs of severe
sepsis are also highly relevant but non-specific. Which
children should be given fluid, what type of fluid, and how
much, are all areas that merit urgent study. A recent study
of aggressive fluid resuscitation in African children with
compensated shock revealed worse outcomes in those
who received fluid boluses with albumin or saline [42], a
surprising finding that was difficult to understand.
Whether aggressive fluid resuscitation in children with
bronchiolitis or pneumonia that present with poor capil-
lary refill and other signs of compensated shock improves
or worsens their outcome is yet to be evaluated.
Rigorous implementation of the Surviving Sepsis guide-
lines will save many lives, but the broad definition of sepsis
makes it likely that the number of children exposed to po-
tentially unnecessary treatments will also increase. An
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agement of the infections subsumed within the term ‘sepsis’
is required to optimize clinical outcomes. This requires
cost-effective implementation of newly available validated
rapid diagnostic tests. Therapy could be streamlined, expos-
ing children only to those antimicrobial agents effective
against the identified pathogen. Immunodiagnostics could
also help guide immunomodulatory therapies [43,44]. Opti-
mizing outcomes in pediatric sepsis requires rigorous re-
search to identify those children that could benefit from
rapid diagnostic testing and targeted antimicrobial treat-
ment and those for whom this is unnecessary.
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The importance of identifying sepsis in the
pre-hospital setting
Ron Daniels (Figure 6) and Tim Nutbeam (Figure 7)
Patients with sepsis are commonly transported to emer-
gency departments by EMS [18,45,46]. These patients tendFigure 6 Ron Daniels is a Consultant in Critical Care based in the
United Kingdom (Birmingham). He is CEO of the UK Sepsis Trust and
Global Sepsis Alliance, and Clinical Adviser on Sepsis to NHS England.
Figure 7 Tim Nutbeam is a consultant emergency physician
and clinical academic based in the United Kingdom (Plymouth).
He is clinical project lead for the UK Sepsis Trust.to have more severe sepsis and have a higher mortality
than those who present by other methods [47]. As dis-
cussed in the previous sections, prompt identification and
early treatment reduces the mortality and morbidity associ-
ated with sepsis. It has been demonstrated in the in-
hospital setting that the earlier this identification and treat-
ment delivery can occur the better a patient’s outcomes
will be [48]. With an average pre-hospital care interval in
excess of 45 minutes for patients with sepsis, early inter-
vention should occur in the pre-hospital setting [16].
Sepsis has not been subject to the public health aware-
ness campaigns that stroke and acute coronary syndromes
have benefited from; as such, public awareness is low. A
recent poll conducted by the UK Sepsis Trust identified
that only 16% of the public were aware that sepsis was a
time-critical condition [49]. These findings mirror similar
surveys conducted in Germany and the USA.
Awareness amongst EMS professionals is also low,
with less than 10% of pre-hospital providers having
knowledge and skills sufficient to pass sepsis-focused
scenarios in a recent survey [50]. This may, in part, be
due to the lack of pre-hospital sepsis dispatch and clin-
ical care protocols or guidelines in many regions [51,52].
Skills availability is also an issue; only about 50% of pa-
tients transported by an EMS system with severe sepsis
will have a paramedic present [16]. The lack of a trained
Box 1: Recommendations for national and regional
strategies to improve sepsis awareness in the pre-
hospital setting
 Widespread public awareness campaigns with clear triggers
for contacting medical or emergency services. Much can be
learnt from the successes of campaigns targeting stroke and
acute coronary syndromes.
 Pre-hospital practitioner education should include ‘sepsis’ as
a significant curriculum element.
 Clear triggers to initiate formal ‘sepsis screening’ by pre-
hospital teams and community practitioners: this screening
may be triggered by a clinical observation-based ‘Early
Warning Score’ or equivalent. This screening should result
in a binary, documented decision of the presence or absence
of sepsis.
 Patients should be risk stratified using clinical observations
(e.g., ‘Red Flag Sepsis’ from the UK Sepsis Trust (Table 2) or
alternative markers, e.g., lactate. High-risk patients should
be pre-alerted to the receiving emergency department.
 Initial resuscitation should begin within the capabilities of
the pre-hospital team – this may be a modified ‘Sepsis Six’
(Table 2) or equivalent.
 The management of pre-hospital sepsis should be subject to
the same measurement and targets as those cases identified
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cluding awareness of sepsis (and its mimics), ability to
screen a patient for the presence of sepsis, and ability to
intervene (e.g., provide intravenous fluids).
There are a number of ways in which sepsis recognition
can be improved in the pre-hospital setting. EMS practi-
tioners should use a screening tool [51] to identify patients
with sepsis. This should trigger the rapid delivery of effect-
ive protocolized care [53,54]. Lactate may be used to risk
stratify patients effectively in the pre-hospital setting [17].
Unfortunately, few EMS systems have established sepsis
care bundles, with the delivery of antibiotics outside of
treatment protocols for suspected meningococcal sepsis
being rare [51]. Even when protocols are available, EMS
crews only successfully identify patients 21% of the time
[47]. Delivery of intravenous fluid administration is
achieved in less than half of cases (and intravenous cannu-
lation in only one-third) with those who do receive fluid
not demonstrating a decreased mortality [16,55].
Delivery to an emergency department by an EMS system
is associated with improved in-hospital processes, demon-
strated by a decreased time to antibiotics and an increased
volume of intravenous fluid therapy [56], with these
processes taking even less time when sepsis was identified in
the pre-hospital environment [47,55]. Despite emergency de-
partment and in-hospital studies repeatedly demonstrating a
decreased mortality with early care, early EMS identification
and treatment have not consistently been associated with
improved outcomes in this patient group [16,51,57] – placing
a pre-hospital IV catheter and delivering fluids does, however,
appear to be associated with a better outcome [18].
Improvement strategies are needed to increase early
sepsis awareness in pre-hospital care at each step of the
process. National and regional strategies should focus on
the steps outlined in Box 1, and further details about clin-
ical tools from the UK Sepsis Trust are given in Table 2.Table 2 The Sepsis Six and Red Flag Sepsis, clinical tools
from the UK Sepsis Trust
Sepsis Six Red Flag Sepsis
1 High-flow oxygen Systolic BP <90 mmHg or MAP
<65 mmHg
2 Blood cultures and consider
source control
Lactate >2 mmol/L
3 Intravenous antibiotics Heart rate >130 per minute
4 Intravenous fluid resuscitation Respiratory rate >25 per minute
5 Check hemoglobin and serial
lactates
Oxygen saturations <91%
6 Hourly urine output measurement Responds only to voice or pain/
unresponsive
Purpuric rash
An immediate care bundle to be
delivered within one hour for patients
with sepsis
A risk stratification tool for
patients with possible sepsisCompeting interests
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